Imatinib Stada

Imatinib, the active ingredient in Imatinib Stada, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is used to treat chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in appropriate patients.

GNH USA supplies Imatinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Imatinib is a targeted tyrosine‑kinase inhibitor used in hematologic and solid‑tumor malignancies. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and induces remission. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves survival by targeting the BCR‑ABL fusion protein. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth by blocking c‑KIT and PDGFR signaling.

Imatinib may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools. - Fatigue: generalized tiredness. - Edema: peripheral swelling. Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe neutropenia: marked decrease in neutrophils. - Pulmonary arterial hypertension: rare increase in pulmonary pressure.

When prescribing Imatinib, clinicians should consider several safety precautions to minimize risk. - Monitor liver function: perform baseline and periodic hepatic enzyme tests. - Assess blood counts: regular CBC to detect neutropenia or thrombocytopenia. - Evaluate cardiac status: echocardiogram for patients with pre‑existing heart disease. - Review drug interactions: avoid concomitant use with strong CYP3A4 inhibitors. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with obstetrician. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Imatinib can interact with other medicines, altering its effectiveness or safety. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase imatinib plasma levels, risk of toxicity. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce imatinib exposure, loss of efficacy. Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may lower absorption, monitor therapeutic response. - Anticoagulants (e.g., warfarin): imatinib may enhance anticoagulant effect, check INR. - Live attenuated vaccines: potential reduced efficacy, consider timing.